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Although jiadifenolide has been reported to neurotrophin-like activity in primary cultured rat cortical
neurons, it is unknown on that of activity in human neurons. Thus, we aimed to assess neurotrophin-like
activity by jiadifenolide in human neuronal cells. We analyzed neuronal precursor cells derived from
human induced pluripotent stem cells for microtuble-associated-protein-2 expression by immunoﬂuo-
rescence and western blot, following jiadifenolide treatment. Jiadifenolide promoted dendrite
outgrowth, facilitated growth, and prevented death in neuronal cells derived from human induced
pluripotent stem cells. Interestingly, jiadifenolide also increased postsynaptic density-95 protein
expression suggesting that jiadifenolide promotes neuronal maturation and post-synaptic formation. We
demonstrate for the ﬁrst time that jiadifenolide exhibits neurotrophic effects on human neuronal pre-
cursor cells.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Neurotrophic factors (neurotrophins) such as nerve growth
factor (NGF), brain-derived neurotrophic factor (BDNF), and
neurotrophin-3 (NT-3) have been reported to prevent neuronal
degeneration, promote neurite regeneration and neuronal survival,
and enhance synaptic plasticity [1,2]. Thus, neurotrophins have
been investigated for therapeutic application in neurological dis-
eases including Alzheimer's disease (AD), Parkinson's disease, and
amyotrophic lateral sclerosis (ALS) that show neurodegenerative,
behavioral, and psychiatric symptoms [3,4]. However, although
neurotrophins act largelywithin the brain, these proteins have high
molecular weights, limiting serum-stability and blood-brain-
barrier passage [5e7]. Moreover, clinical trials of NGF and BDNF
have failed [8]. Thus, novel small-molecule neurotrophin-like
compounds are needed, which lack such pharmacological
disadvantages.
Jiadifenolide (Fig. 1), a seco-prezizaane-type sesquiterpenoid,y, Faculty of Pharmaceutical
ihama-Houji, Yamashirocho,
uhara).
Inc. This is an open access article uwas isolated from the pericarps of Illicium jiadifengpi collected in
Southwestern China [9], and was chemically synthesized [10]. Jia-
difenolide has very unique chemical structure (Fig. 1) [9, 10]. Jia-
difenolide and derivatives have been reported to promote neurite
outgrowth in primary cultured rat cortical neurons [9] and enhance
NGF activity, thereby facilitating differentiation of PC12 cells (a rat
adrenal pheochromocytoma cell line) [11]. Thus, previous studies
suggest these compounds have neurotrophin-like effects in rat
neurons. However, owing to species differences, there have been
limitations in accurately predicting the clinical activities and
adverse effects of jiadifenolide in human neurons. Therefore, prior
to conducting clinical trials, an investigation of the neurotrophic
effects of jiadifenolide on human neurons is necessary.2. Materials and methods
2.1. Preparation of jiadifenolide
Jiadifenolide (Fig. 1) as chemically synthesized from neomajucin
isolated from the pericarps of Illicium jiadifengpi, and puriﬁed as
previously reported [9]. We dissolved synthetic jiadifenolide in
dimethyl sulfoxide (DMSO) at a concentration of 10 mM for stock
solutions.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chemical structure of jiadifenolide.
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Human induced pluripotent stem cells (hiPSCs) (line 201B7; Cell
No. HPS0063) [12], were purchased from a cell bank (Riken Bio-
resource Center, Ibaraki, Japan). Cells were maintained on a
mitomycin-C (Kyowa Hakko Kirin, Tokyo, Japan)-treated SNL 76/7
feeder-cell (DS Pharma Biomedical, Osaka, Japan) layer at 37 C and
5% CO2. Cells were grown in a primate embryonic stem cell medium
(ReproCELL, Kanagawa, Japan), supplemented with 4 ng/mL basic
ﬁbroblast growth factor (Wako, Osaka, Japan) and 50 U/mL peni-
cillin with 50 mg/mL streptomycin (P/S; Life Technologies, CA, USA).
2.3. Induction of neuronal precursor cell differentiation
Differentiation of neuronal precursor cells from hiPSCs was
induced by serum-free culture of embryoid body-like aggregates,
quick (SFEBq) method [13,14] (Fig. 2, stages I and II). Brieﬂy, hiPSCs
cultured on a mitomycin C-treated SNL feeder-cell layer were
treated with 10 mM Y-27632, Rho-associated coiled-coil forming
kinase/Rho-associated kinase inhibitor, (Wako, Osaka, Japan), and
were dissociated into single cells using TrypLE™ Select solution
(Life Technologies) after removing feeder cells using CTK solution
(2.5% trypsin [Life Technologies], 1 mg/mL collagenase IV [LifeFig. 2. Experimental procedure for neuronal cell differentiation and maturation from hiPSCs
was added at stage III. Immunoﬂuorescent staining and western blots were performed on ne
post-incubation, respectively. Additional details are described in Materials and Methods.Technologies], 0.1 M CaCl2 and 20% knockout serum replacement
[KSR; Life Technologies] in H2O). The hiPSCs were aggregated in a
low-binding, U-bottomed, 96-well plate at 37 C and 5% CO2 and 5%
DFK medium (5% KSR [Life Technologies], 100 mM modiﬁed Eagle
medium, nonessential amino acids solution [Life Technologies],
2 mM L-glutamine, 110 mM 2-mercaptoethanol [Life Technologies],
and P/S [Life Technologies] in glucose-Dulbecco's modiﬁed Eagle
medium (DMEM)/F12 medium [Life Technologies], supplemented
with 10 mM Y-27632, 2 mM dorsomorphin (Calbiochem, CA, USA)
and 10 mM SB431542, transforming growth factor b1 superfamily
activin receptor-like kinase inhibitor, (Stemgent, MA, USA) for
embryoid-body (EB) formation and neuronal induction (Fig. 2,
stage I). Half of media inwells was changed with 5% DFKmedium at
either 3 or 4 days of incubation. After 10e12 days of incubation, EBs
were transferred onto a Matrigel matrix (Corning, MA, USA)-coated
6-well plate and cultured for 16 days at 37 C and 5% CO2 with 5%
DFK medium supplemented with 1% N2 supplement (Life Tech-
nologies), 2 mM dorsomorphin, and 10 mM SB431542. Neuronal
precursor cells were removed from EB cores [14] (Fig. 2, stage II).2.4. Maturation of neuronal cells
The procedure used to induce neuronal maturation was per-
formed as indicated in Fig. 2, stage III. Neuronal precursor cells
removed from EB cores were dissociated into single cells with an
accutase (Life Technologies), and were then cultured on both 0.01%
poly-L-ornithine (Sigma, MO, USA) and 3.3 mg/mL laminin (Sigma)-
coated 24-well plates at 37 C and 5% CO2, with neurobasal medium
(Life Technologies), supplemented with 2% B-27 supplement (Life
Technologies) and P/S. Depending on treatment conditions, media
also contained one of the following: (i) 0.25% DMSO (as a negative
control); (ii) neurotrophins (as a positive control; 10 ng/mL re-
combinant human BDNF [Wako], 10 ng/mL recombinant human
glial-cell derived neurotrophic factor [GDNF; Wako], and 10 ng/mL
recombinant human NT-3 [Wako] [14]); or (iii) 1, 5, 10, or 25 mM
jiadifenolide (Fig. 2, stage III). Media in wells was changed at either
3 or 4 days of incubation.. To evaluate the neurotrophic effects of jiadifenolide on human neurons, Jiadifenolide
uronal precursor cells derived from hiPSCs treated with (i), (ii), or (iii), at 30 or 40 days
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At 30 days of incubation (Fig. 2, stage III), mature cells were ﬁxed
with Cytoﬁx™ ﬁxation buffer (Becton Dickinson [BD], NJ, USA) for
10 min at room temperature (R/T), and permeabilized with BD
Phosﬂow™ Perm Buffer III (BD) for 5 min at R/T. After washing cells
with Perm/Wash™ Buffer solution (BD), the cells were blocked
using Pharmingen™ Stain Buffer (with fetal bovine serum) (BD).
For neuronal dendrite immunoﬂuorescent staining, we used pri-
mary mouse anti-microtubule-associated protein 2 (MAP2; a neu-
rite marker) monoclonal antibodies (HM-2, Abcam, Cambridge,
UK), and Alexa ﬂuor 488-conjugated goat anti-mouse IgG second-
ary antibodies (Life Technologies). Cell nuclei were then stained
using diamidino-2-phenylindole (DAPI; Life Technologies). Wells
were photographed under a ﬂuorescencemicroscope (BIOREVO BZ-
9000, Keyence, Osaka, Japan). Using the IN Cell Investigator image-
analysis software (GE Healthcare, Bucks, UK), the total neurite area
(mm2), total neurite length (mm), and neuronal cell numbers were
measured as based on MAP2-positive area, length, or DAPI-positve
cell numbers, respectively.
2.6. Western blotting
At 40 days of incubation (Fig. 2, stage III), cells were lysed with a
sodium dodecyl sulfate buffer (125 mM TriseHCl [pH 6.8], 5% so-
dium dodecyl sulfate, 25% glycerol, 0.1% bromophenol blue, and 10%
b-mercaptoethanol) and boiled for 5 min. Cell lysates were then
loaded onto a 6e10% polyacrylamide gel. Resulting proteins were
transferred to a polyvinylidene ﬂuoride microporous membrane
(Millipore, MA, USA). Mouse anti-MAP2 monoclonal (HM-2,
Abcam) or rabbit anti-postsynaptic density-95 (PSD95; a post-
synaptic marker) polyclonal (ab18258, Abcam) primary antibodies
were used to detect MAP2 or PSD95 proteins, respectively. Rabbit
anti-beactin antibodies (13E5; Cell Signaling, MA, USA) were used
as an internal control. Horseradish peroxidase-conjugated goat
anti-mouse IgG antibodies (SouthernBiotech, AL, USA), or goat anti-
rabbit IgG antibodies (KPL, MD, USA) were used as secondary an-
tibodies. Blots were developed using Western Lightning ECL Pro
(PerkinElmer, MA, USA). Protein-band intensities were measured
using ImageJ software. MAP2 and PSD95 protein levels were
normalized to that of b-actin.
2.7. Statistical analysis
All results are expressed as means ± standard error of the mean
(SEM). Differences were analyzed for statistical signiﬁcance using
one-way analysis of variance (ANOVA), which facilitates compari-
son among more than three groups. Signiﬁcance levels were
determined at p < 0.05.
3. Results
3.1. Jiadifenolide promoted neuronal dendritic outgrowth, and
increased human neuronal cell numbers
It has been reported that neurotrophins, such as NGF, BDNF, NT-
3, and GDNF, promote neurite regeneration, neuron survival, and
synapse maturation, including synaptic construction and plasticity
[1,2,15]. To investigate whether jiadifenolide exhibits neurotrophic
activity in human neurons, we therefore used neuronal precursor
cells induced from hiPSCs using SFEBq method (Fig. 2).
To evaluate the neurite outgrowth, we ﬁrst performed immu-
noﬂuorescent staining for MAP2, neuronal dendritic marker, at 30
days of incubation, as shown in Fig. 2, stage III. Compared with
0.25% DMSO (a negative control), neurotrophins, (a mixture ofBDNF, GDNF and NT-3; a positive control), and 1 or 10 mM jiadife-
nolide promoted neurite extension (Fig. 3A), and signiﬁcantly
increased total neurite area and length (Fig. 3B and C) in iPSC-
derived neuronal cells. These results demonstrate that jiadifeno-
lide promotes dendrite outgrowth in human neurons. Additionally,
treatment with both neurotrophins and 1 mM jiadifenolide signif-
icantly increased the number of neuronal cells (DAPI-positive cells)
(Fig. 3D), suggesting that jiadifenolide promoted the growth, or
prevented the death, of human neuronal cells.
Neurotrophic effects were achieved at similar jiadifenolide
concentrations for human neuronal cells (Fig. 3) as those for pri-
mary cultured rat cortical neurons [9]. These data demonstrated
that, similar to rat neurons, jiadifenolide exhibits neurotrophic ef-
fects in human neuronal cells.
3.2. Jiadifenolide promoted synaptic maturation in human
neuronal cells
To evaluate whether jiadifenolide promotes synaptic matura-
tion in human neuronal cells, we analyzed the protein expression of
MAP2 and PSD95 (a post-synaptic marker) using western blotting
at 40 days of incubation (Fig. 2, stage III). Compared with 0.25%
DMSO, neurotrophins and jiadifenolide (1 and 5 mM) signiﬁcantly
increased MAP2 protein expression in neuronal cells derived from
hiPSCs (Fig. 4A and B). Interestingly, we also found that 1 and 5 mM
jiadifenolide signiﬁcantly increased PSD95 protein expression
(Fig. 4A and C). It has been reported that the increase of PSD95
expression in neurons promotes the maturation of excitatory syn-
apses, such as those in glutamatergic neurons [16e18]. These data
suggest that jiadifenolide promotes synaptic maturation in human
neurons.
4. Discussion
AD is characterized by neuronal and synaptic degeneration,
apoptosis, neuroinﬂammation, and autophagy, which are induced
by accumulation of abnormally folded amyloid-b (Ab) and tau
proteins [19]. These neurodegenerative events can subsequently
lead to behavioral and psychiatric disorders including depression,
agitation, and apathy [20]. Among these symptoms, depression is
frequency observed in patients with AD, with a prevalence of be-
tween 20 and 50% [20]. Shankar et al. reported that Ab protein
dimers derived from the brains of human patients with Alzheimer's
disease impaired synaptic plasticity, reduced dendritic spine den-
sity, and disrupted memories of learned behaviors in rats [21]. In
transgenic ADmice, loss of the pre-synaptic protein synaptophysin,
the post-synaptic protein PSD95, and the glutamate receptor sub-
unit GluR1, have also been observed [22e26]. Reduction of neuro-
genesis and synaptophysin and the loss of dendritic spines have
also been observed in rat depression models [27,28]. We demon-
strated that jiadifenolide promoted dendritic outgrowth and
overall cell growth (or prevented cell death), and increased MAP2
and PSD95 protein expression in human neurons (Figs. 3 and 4).
These results suggest that jiadifenolide may improve characteristic
symptoms, such as depression, in patients with AD. We showed
that, among concentrations of 1e25 mM,1 mM jiadifenolide had the
greatest efﬁcacy on the neurons in our study (Figs. 3 and 4). This
lower-dose efﬁcacy was similar to that observed in primary
cultured rat cortical neurons [9]. In experiments using ethanol-
treated rats, low doses of ethanol improved memory and
increased NMDA-receptor GluN1 subunit expression, whereas high
doses of ethanol reduced neurogenesis, diminished NMDA-
receptor GluN2B subunit expression, and impaired visual memory
[29]. In addition, low ethanol increased the expression of tropo-
myosin receptor kinase (Trk) B receptor protein in CA3 region of rat
Fig. 3. Immunoﬂuorescent MAP2 staining of human neuronal cells treated with jiadifenolide. At 30 days of incubation (Fig. 2, stage III), the cells were ﬁxed and permeabilized. To
visualize neuronal dendrites, we performed immunoﬂuorescent staining for MAP2, a neurite marker, and DAPI, a nucleus-staining compound. Each well was treated with (i) 0.25%
DMSO, (ii) neurotrophins or 1e25 mM jiadifenolide, respectively. Cells were subsequently photographed under a ﬂuorescence microscope (A). The white scale bar in each image
represented 100 mm. Images in (A) (n ¼ 6 each) were analyzed using IN Cell Investigator image-analysis software. Total neurite area (mm2) (B), total neurite length (mm) (C), and the
number of neuronal cells (DAPI-positive cells) (D) were measured. Data are presented as means ± SEM of three independent experiments. *p < 0.05 and ***p < 0.001, compared with
DMSO treatment, respectively.
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dorsal hippocampus of ethanol-fed rats [29,30]. Thus, these results
suggest that low ethanol would improve the memory by increasing
NMDA-receptor GluN1 subunit expression and enhancing BDNF-
TrkB neurotrophic pathway. In a similar manner, moderate jiadi-
fenolide doses may lead to neurotrophic effects, both in human and
rat neurons.
Although we showed that jiadifenolide exhibits neurotrophic
activity in human neuronal precursor cells, the underlying molec-
ular mechanisms remain unclear. Neurotrophins, such as NGF,
BDNF and NT-3, act via two receptors: the p75 neurotrophin re-
ceptor (p75NTR) and the Trk receptor. p75NTR binds to all neuro-
trophins extracellularly; this signal is then transduced
intracellularly via the phosphoinositide 3-kinase (PI3K), mitogen-
activated protein kinase (MAPK), and nuclear factor-kB (NF-kB)
pathways [1,2]. Signaling via p75NTR induces cell survival, cell
death, regulation of proliferation, and inhibition of neurite
outgrowth [1,2]. Trk receptors consist of the TrkA, TrkB and TrkC
subtypes, which have intracellular-tyrosine-kinase and
extracellular-neurotrophin-binding domains. Each receptorsubtype binds to a different neurotrophin: NGF binds with TrkA,
and BDNF and NT3 bind with TrkB and TrkC, respectively [1,2]. Each
neurotrophin-Trk receptor interaction induces phosphorylation of
intracellular-domain tyrosine residues via autophosphorylation
[1,2]. Trk-phosphorylation signaling is then transmitted to the
MAPK, PI3K, or phospholipase Cg1 (PLCg) pathways, which ulti-
mately promotes neurite outgrowth, cell survival, and differentia-
tion [1,2]. Additionally, BDNF signaling increases PSD95 protein
expression in synapses and dendritic spines [31,32], and the MAPK,
PI3K, and PLCg pathways mediated via TrkB regulate post-synaptic
localization of PSD95 [33]. Taken together, these results suggest
that TrkB signaling pathways may be implicated in the neuro-
trophic effects of jiadifenolide on human neurons.
Cells differentiated from hiPSCs, such as neurons and hepato-
cytes, have been used as a new tool to predict the clinical safety and
efﬁcacy of drug candidates [34]. Pre-clinical experiments using cells
derived from hiPSCs have the advantages of overcoming species
differences, improving the replacement, reﬁnement, and reduction
of animal experiments, and reducing drug-development costs.
Pardridge has suggested in a review that small-molecule
Fig. 4. Western blot analysis of MAP2 and PSD95 expression in jiadifenolide-treated
human neuronal cells. At 40 days of incubation (Fig. 2, stage III), cells treated with i)
0.25% DMSO, ii) neurotrophins, or iii) 1e25 mM jiadifenolide were lysed, respectively.
Protein expression of MAP2 and PSD95 (a post-synaptic marker) were analyzed in each
cell lysate by western blot (A). Band intensities were measured and normalized to that
of b-actin. MAP2 (n ¼ 3e4) (B) and PSD95 (n ¼ 4e5) (C) protein levels were
normalized to those of DMSO-treated cells (set as 1). Data are presented as the
mean ± SEM of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 for
the comparisons of DMSO.
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400 and form eight or fewer hydrogen bonds may cross the
bloodebrain barrier (BBB) via lipid-mediated diffusion [35]. Jiadi-
fenolide, with a MW of 310.11, has two hydroxy groups in the
chemical structure (Fig. 1). Thus, jiadifenolide possesses the prop-
erties of a small molecule that is expected to have high BBB
permeability. Moreover, Lu et al. recently reported that jiadifeno-
lide can be synthesized in gram amounts using as few as eight steps
[36]. Thus, in terms of synthesis efﬁciency and bioavailability, jia-
difenolide is a strong potential drug candidate for clinical-trial
evaluation in the treatment of human neurological disorders.
We evaluated the pre-clinical neurotrophic effects of jiadifeno-
lide on human neurons using neuronal cells derived from hiPSCs.
By performing image analysis of neuronal cells and MAP2 andPSD95 protein expression, we demonstrated that jiadifenolide
promoted dendritic outgrowth, and facilitated cell growth (or
prevented death) in human neuronal cells derived from iPSCs.
These results suggest that jiadifenolide exhibits neurotrophin-like
effects in human neuron, and is a promising drug candidate for
treatment of neurological diseases.
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